Hasil ini sesuai dengan penelitian sebelumnya di yang dilakukan oleh Amalia DKK (2020) mayoritas

sebanyak (58,6%) jenis stroke lakunar dan presentase yang paling sedikit cardioemboli (20,7%). 2
Pada penelitian yang dilakukan oleh Barrow et al (2019) pada pasien stroke lakunar tanpa mendapat
terapi trombolisis memiliki outcome yang baik pada 24 dari 52 pasien (46%).1

Studi yang dilakukan oleh Wibisono (2012) mayoritas sebanyak 61,9% dari 84 subjek penelitian
mengalami stroke iskemik di daerah subkorteks.3

daftar pustaka

1. Barow E, Boutitie F, Cheng B, Cho TH, Ebinger M, Endres M, Fiebach JB, Fiehler J, Ford I,
Galinovic I, Nickel A. Functional outcome of intravenous thrombolysis in patients with lacunar
infarcts in the WAKE-UP trial. JAMA neurology. 2019 Jun 1;76(6):641-9.
2. Amalia LI, Furqani MA, Parwati I, Rizal AH, Panigoro RA. Correlation between Alberta stroke
programme early computed tomography score (ASPECTS) and National Institute of health
stroke score (NIHSS) in ischemic stroke. Sains Malays. 2020;49(5):1115-20.
3. Wibisono, Dhimas Handoko. Hubungan Antara Stroke Iskemik Akibat Dislipidemia Dan
Lokasi Infark Di RSUD Dr. Moewardi Di Surakarta. Diss. Universitas Muhammadiyah
Surakarta, 2012.

Results of the analysis of efficacy outcomes in 105 patients with

lacunar stroke with available information for clinical endpoints
are provided in Table 2. In the subgroup of patients with lacunar stroke, favorable outcome was observed in 31 of 53 patients (59%) in the
alteplase group and in 24 of 52 patients
(46%) in the placebo group (absolute difference, 12%; adjusted OR, 1.67 [95% CI, 0.77-3.64]; P = .20). The distribution
of mRS scores at 90 days after stroke showed a nonsignificant
difference in outcomes (adjusted common OR, 1.94 [95% CI,
0.95-3.93]; P = .07; Figure 3). Analysis of treatment response
showed a significant benefit of treatment with alteplase with
treatment response observed in 19 patients (36%) in the alteplase group compared with 7 patients (14%) in the placebo
group (adjusted OR, 3.70 [95% CI, 1.38-9.87]; P = .009). There
were further trends in favor of treatment with alteplase for the
Global Outcome Score and